{"id":7075,"date":"2024-02-21T17:45:20","date_gmt":"2024-02-21T12:15:20","guid":{"rendered":"https:\/\/pharmaceuticalcarrier.com\/?p=7075"},"modified":"2024-02-21T17:45:40","modified_gmt":"2024-02-21T12:15:40","slug":"standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions","status":"publish","type":"post","link":"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/","title":{"rendered":"Standard Operating Procedure (SOP) for Testing Bioburden of Fractional Solutions"},"content":{"rendered":"\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-transparent ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#1_Purpose\" >1. Purpose:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#2_Scope\" >2. Scope:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#3_Responsibilities\" >3. Responsibilities:<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#31_Quality_Assurance_QA\" >3.1 Quality Assurance (QA):<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#32_Microbiology_Department\" >3.2 Microbiology Department:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#33_Testing_Personnel\" >3.3 Testing Personnel:<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#4_Materials_and_Equipment\" >4. Materials and Equipment:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#5_Procedure\" >5. Procedure:<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#51_Sample_Collection\" >5.1 Sample Collection:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#52_Dilution\" >5.2 Dilution:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#53_Inoculation\" >5.3 Inoculation:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#54_Enumeration\" >5.4 Enumeration:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#55_Reporting\" >5.5 Reporting:<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#6_Acceptance_Criteria\" >6. Acceptance Criteria:<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#61_Purpose\" >6.1. Purpose:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#62_Scope\" >6.2. Scope:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#63_Definitions\" >6.3. Definitions:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#64_Acceptance_Criteria\" >6.4. Acceptance Criteria:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#65_Sampling_Plan\" >6.5. Sampling Plan:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#66_Testing_Methodology\" >6.6. Testing Methodology:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#67_Trend_Analysis\" >6.7. Trend Analysis:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#68_Deviations\" >6.8. Deviations:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#69_Reporting\" >6.9. Reporting:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#610_Review_and_Approval\" >6.10. Review and Approval:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#611_Training\" >6.11. Training:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#612_Revision_History\" >6.12. Revision History:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#613_References\" >6.13. References:<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#7_Documentation\" >7. Documentation:<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#71_Purpose\" >7.1. Purpose:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#72_Scope\" >7.2. Scope:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-31\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#73_Documentation_Requirements\" >7.3. Documentation Requirements:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-32\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#74_Record_Keeping\" >7.4. Record Keeping:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-33\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#75_Review_and_Approval\" >7.5. Review and Approval:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-34\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#76_Training\" >7.6. Training:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-35\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#77_Revision_History\" >7.7. Revision History:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-36\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#78_References\" >7.8. References:<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-37\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#8_Deviation_Handling\" >8. Deviation Handling:<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-38\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#81_Purpose\" >8.1. Purpose:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-39\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#82_Scope\" >8.2. Scope:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-40\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#83_Definitions\" >8.3. Definitions:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-41\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#84_Identification_of_Deviation\" >8.4. Identification of Deviation:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-42\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#85_Documentation_of_Deviation\" >8.5. Documentation of Deviation:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-43\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#86_Investigation\" >8.6. Investigation:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-44\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#87_Corrective_Actions\" >8.7. Corrective Actions:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-45\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#88_Review_and_Approval\" >8.8. Review and Approval:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-46\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#89_Reporting\" >8.9. Reporting:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-47\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#810_Training\" >8.10. Training:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-48\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#811_Revision_History\" >8.11. Revision History:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-49\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#812_References\" >8.12. References:<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-50\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#9_Training\" >9. Training:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-51\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#10_Revision_History\" >10. Revision History:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-52\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#11_References\" >11. References:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-53\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#12_Approval\" >12. Approval:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-54\" href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/2024\/02\/21\/standard-operating-procedure-sop-for-testing-bioburden-of-fractional-solutions\/#13_Distribution\" >13. Distribution:<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"1_Purpose\"><\/span><strong>1. Purpose:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>1.1 This SOP outlines the procedure for testing the bioburden of fractional solutions to ensure compliance with quality standards.<\/p><div class=\"pharm-content\" id=\"pharm-900425089\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-8402705006112223\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-8402705006112223\" \ndata-ad-slot=\"7652789694\" \ndata-ad-format=\"auto\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"2_Scope\"><\/span><strong>2. Scope:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>2.1 This procedure applies to all fractional solutions used in the manufacturing process.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"3_Responsibilities\"><\/span><strong>3. Responsibilities:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"31_Quality_Assurance_QA\"><\/span><strong>3.1 Quality Assurance (QA):<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>3.1.1 Oversee the implementation and adherence to this SOP. <\/p>\n\n\n\n<p>3.1.2 Verify that testing personnel are appropriately trained and qualified. <\/p>\n\n\n\n<p>3.1.3 Review and approve any deviations from the acceptance criteria.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"32_Microbiology_Department\"><\/span><strong>3.2 Microbiology Department:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>3.2.1 Conduct bioburden testing in accordance with established procedures. <\/p>\n\n\n\n<p>3.2.2 Ensure the availability and proper functioning of equipment and materials required for testing. <\/p>\n\n\n\n<p>3.2.3 Report any abnormalities or deviations to QA promptly.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"33_Testing_Personnel\"><\/span><strong>3.3 Testing Personnel:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>3.3.1 Wear appropriate personal protective equipment, including sterile gloves, during sample collection. 3.3.2 Aseptically collect and handle samples according to specified procedures. <\/p>\n\n\n\n<p>3.3.3 Dilute samples accurately and transfer them to culture media following aseptic techniques. <\/p>\n\n\n\n<p>3.3.4 Record all relevant information, including sample details and dilution factors. <\/p>\n\n\n\n<p>3.3.5 Perform colony counting and document results accurately. <\/p>\n\n\n\n<p>3.3.6 Report any issues or concerns encountered during the testing process to the Microbiology Department.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"4_Materials_and_Equipment\"><\/span><strong>4. Materials and Equipment:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>4.1 Sterile containers for sample collection <\/p>\n\n\n\n<p>4.2 Sterile pipettes <\/p>\n\n\n\n<p>4.3 Sterile diluent <\/p>\n\n\n\n<p>4.4 Culture media <\/p>\n\n\n\n<p>4.5 Incubator <\/p>\n\n\n\n<p>4.6 Colony counter <\/p>\n\n\n\n<p>4.7 Sterile gloves<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Procedure\"><\/span><strong>5. Procedure:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"51_Sample_Collection\"><\/span><strong>5.1 Sample Collection:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>5.1.1 Wear sterile gloves during sample collection. <\/p>\n\n\n\n<p>5.1.2 Collect the fractional solution aseptically in a sterile container.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"52_Dilution\"><\/span><strong>5.2 Dilution:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>5.2.1 Aseptically transfer a suitable volume of the sample into a sterile diluent. <\/p>\n\n\n\n<p>5.2.2 Mix thoroughly to ensure homogeneity.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"53_Inoculation\"><\/span><strong>5.3 Inoculation:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>5.3.1 Inoculate the appropriate dilutions onto culture media using sterile pipettes. <\/p>\n\n\n\n<p>5.3.2 Incubate the inoculated media at the specified temperature and duration.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"54_Enumeration\"><\/span><strong>5.4 Enumeration:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>5.4.1 After incubation, count the colonies using a colony counter. <\/p>\n\n\n\n<p>5.4.2 Record the colony-forming units (CFUs) per milliliter.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"55_Reporting\"><\/span><strong>5.5 Reporting:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>5.5.1 Compile the test results, including the bioburden count. <\/p>\n\n\n\n<p>5.5.2 Report any deviations from the acceptance criteria.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"6_Acceptance_Criteria\"><\/span><strong>6. Acceptance Criteria:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"61_Purpose\"><\/span>6.<strong>1. Purpose:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>1.1 This SOP establishes the acceptance criteria for bioburden testing of fractional solutions to ensure compliance with quality standards.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"62_Scope\"><\/span>6.<strong>2. Scope:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>2.1 Applicable to all bioburden testing activities involving fractional solutions within the organization.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"63_Definitions\"><\/span>6.<strong>3. Definitions:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>3.1 <strong>Bioburden:<\/strong> The number of viable microorganisms present in a sample.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"64_Acceptance_Criteria\"><\/span>6.<strong>4. Acceptance Criteria:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>4.1 General Criteria:<\/strong> <\/p>\n\n\n\n<p>4.1.1 The bioburden count should not exceed the established limits specified in regulatory guidelines. 4.1.2 No microbial contamination should be detected in the negative control samples.<\/p>\n\n\n\n<p><strong>4.2 Specific Criteria:<\/strong> <\/p>\n\n\n\n<p>4.2.1 For [Your Industry] applications, the acceptance criteria may vary. Refer to industry-specific guidelines and standards for detailed specifications. 4.2.2 Criteria for specific microorganisms may be outlined separately based on the nature of the fractional solutions.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"65_Sampling_Plan\"><\/span>6.<strong>5. Sampling Plan:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>5.1 Define the sampling plan based on batch size and production frequency. 5.2 Randomly select samples from different batches for bioburden testing.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"66_Testing_Methodology\"><\/span>6.<strong>6. Testing Methodology:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>6.1 Utilize validated testing methods and procedures for bioburden determination. 6.2 Ensure testing personnel follow aseptic techniques during sample collection and testing.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"67_Trend_Analysis\"><\/span>6.<strong>7. Trend Analysis:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>7.1 Conduct trend analysis on bioburden data over time. 7.2 Evaluate any significant variations and implement corrective actions if trends indicate a potential issue.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"68_Deviations\"><\/span>6.<strong>8. Deviations:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>8.1 If the bioburden count exceeds the acceptance criteria, classify it as a deviation. 8.2 Initiate an investigation to determine the root cause and implement corrective actions promptly.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"69_Reporting\"><\/span>6.<strong>9. Reporting:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>9.1 Document and report all bioburden test results, including adherence or deviation from acceptance criteria. <\/p>\n\n\n\n<p>9.2 Maintain records in a secure and accessible manner.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"610_Review_and_Approval\"><\/span>6.<strong>10. Review and Approval:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>10.1 QA is responsible for reviewing and approving the acceptance criteria. <\/p>\n\n\n\n<p>10.2 Regularly review and update the acceptance criteria in consultation with relevant stakeholders.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"611_Training\"><\/span>6.<strong>11. Training:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>11.1 Ensure that testing personnel are trained on the acceptance criteria and any updates. <\/p>\n\n\n\n<p>11.2 Maintain records of training sessions.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"612_Revision_History\"><\/span>6.<strong>12. Revision History:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>12.1 Document all revisions made to the acceptance criteria. <\/p>\n\n\n\n<p>12.2 Clearly communicate any changes to relevant personnel.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"613_References\"><\/span>6.<strong>13. References:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>13.1 List any relevant documents, guidelines, or standards referenced in this SOP.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"7_Documentation\"><\/span><strong>7. Documentation:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"71_Purpose\"><\/span>7.<strong>1. Purpose:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>1.1 This SOP outlines the documentation requirements for the bioburden testing of fractional solutions to ensure accuracy, traceability, and compliance with quality standards.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"72_Scope\"><\/span>7.<strong>2. Scope:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>2.1 Applicable to all documentation generated during the bioburden testing process for fractional solutions within the organization.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"73_Documentation_Requirements\"><\/span>7.<strong>3. Documentation Requirements:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>3.1 Sample Collection:<\/strong> <\/p>\n\n\n\n<p>3.1.1 Record the date and time of sample collection. <\/p>\n\n\n\n<p>3.1.2 Clearly label each sample with a unique identifier, including batch information.<\/p>\n\n\n\n<p><strong>3.2 Dilution and Inoculation:<\/strong> <\/p>\n\n\n\n<p>3.2.1 Document the dilution factors and volumes used during the sample preparation.<\/p>\n\n\n\n<p>3.2.2 Record the details of the inoculation process onto culture media.<\/p>\n\n\n\n<p><strong>3.3 Incubation:<\/strong> <\/p>\n\n\n\n<p>3.3.1 Log the start and end times of the incubation period. <\/p>\n\n\n\n<p>3.3.2 Monitor and record any unusual observations during incubation.<\/p>\n\n\n\n<p><strong>3.4 Enumeration:<\/strong> <\/p>\n\n\n\n<p>3.4.1 Document the colony counts for each sample. <\/p>\n\n\n\n<p>3.4.2 Include information on the method of enumeration and any specific observations.<\/p>\n\n\n\n<p><strong>3.5 Acceptance Criteria:<\/strong> <\/p>\n\n\n\n<p>3.5.1 Clearly state the acceptance criteria applied to each bioburden test.<\/p>\n\n\n\n<p> 3.5.2 Document any deviations from the acceptance criteria.<\/p>\n\n\n\n<p><strong>3.6 Trend Analysis:<\/strong> <\/p>\n\n\n\n<p>3.6.1 Conduct trend analysis on bioburden data over time. <\/p>\n\n\n\n<p>3.6.2 Record any actions taken based on trend analysis results.<\/p>\n\n\n\n<p><strong>3.7 Deviations:<\/strong> <\/p>\n\n\n\n<p>3.7.1 Document all deviations from established procedures. <\/p>\n\n\n\n<p>3.7.2 Outline the investigation process and corrective actions taken.<\/p>\n\n\n\n<p><strong>3.8 Reporting:<\/strong> <\/p>\n\n\n\n<p>3.8.1 Prepare a comprehensive report summarizing the bioburden testing results. <\/p>\n\n\n\n<p>3.8.2 Include information on adherence to acceptance criteria and any deviations.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"74_Record_Keeping\"><\/span>7.<strong>4. Record Keeping:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>4.1 Storage:<\/strong> <\/p>\n\n\n\n<p>4.1.1 Store all documents in a secure and controlled environment. <\/p>\n\n\n\n<p>4.1.2 Ensure accessibility to authorized personnel only.<\/p>\n\n\n\n<p><strong>4.2 Retention Period:<\/strong> <\/p>\n\n\n\n<p>4.2.1 Establish a retention period for bioburden testing documents in accordance with regulatory requirements. <\/p>\n\n\n\n<p>4.2.2 Safely dispose of records after the designated retention period.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"75_Review_and_Approval\"><\/span>7.<strong>5. Review and Approval:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>5.1 QA is responsible for reviewing and approving all documentation related to bioburden testing. <\/p>\n\n\n\n<p>5.2 Conduct periodic reviews to ensure completeness and accuracy of records.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"76_Training\"><\/span>7.<strong>6. Training:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>6.1 Provide training to personnel involved in documentation procedures. <\/p>\n\n\n\n<p>6.2 Maintain records of training sessions.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"77_Revision_History\"><\/span>7.<strong>7. Revision History:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>7.1 Document all revisions made to the documentation procedures. <\/p>\n\n\n\n<p>7.2 Clearly communicate any changes to relevant personnel.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"78_References\"><\/span>7.<strong>8. References:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>8.1 List any relevant documents, guidelines, or standards referenced in this SOP.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"8_Deviation_Handling\"><\/span><strong>8. Deviation Handling:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"81_Purpose\"><\/span>8.<strong>1. Purpose:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>1.1 This SOP outlines the procedures for identifying, documenting, investigating, and resolving deviations encountered during the testing of bioburden for fractional solutions.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"82_Scope\"><\/span>8.<strong>2. Scope:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>2.1 Applicable to all personnel involved in bioburden testing and quality assurance within the organization.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"83_Definitions\"><\/span>8.<strong>3. Definitions:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>3.1 <strong>Deviation:<\/strong> Any departure from established procedures or acceptance criteria.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"84_Identification_of_Deviation\"><\/span>8.<strong>4. Identification of Deviation:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>4.1 Personnel Responsibility:<\/strong> <\/p>\n\n\n\n<p>4.1.1 All personnel involved in the bioburden testing process are responsible for promptly identifying and reporting any deviations. <\/p>\n\n\n\n<p>4.1.2 Deviations may include, but are not limited to, equipment malfunctions, procedural errors, or unexpected observations.<\/p>\n\n\n\n<p><strong>4.2 Quality Assurance (QA) Notification:<\/strong> <\/p>\n\n\n\n<p>4.2.1 Immediately inform the QA department of any identified deviation. <\/p>\n\n\n\n<p>4.2.2 Provide a detailed description of the deviation, including relevant dates, times, and potential impact on testing results.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"85_Documentation_of_Deviation\"><\/span>8.<strong>5. Documentation of Deviation:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>5.1 Deviation Report:<\/strong> <\/p>\n\n\n\n<p>5.1.1 QA will initiate a deviation report, including a unique identifier for tracking purposes. <\/p>\n\n\n\n<p>5.1.2 Clearly document the nature of the deviation, its potential impact, and initial corrective actions taken.<\/p>\n\n\n\n<p><strong>5.2 Supporting Documentation:<\/strong> <\/p>\n\n\n\n<p>5.2.1 Attach relevant documentation, such as photographs, data logs, or any other evidence related to the deviation. <\/p>\n\n\n\n<p>5.2.2 Provide information on the personnel involved and the steps leading to the identification of the deviation.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"86_Investigation\"><\/span>8.<strong>6. Investigation:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>6.1 QA-Led Investigation:<\/strong> <\/p>\n\n\n\n<p>6.1.1 QA will lead a thorough investigation into the deviation. <\/p>\n\n\n\n<p>6.1.2 Analyze root causes, involving relevant personnel and departments as necessary.<\/p>\n\n\n\n<p><strong>6.2 Timelines:<\/strong> <\/p>\n\n\n\n<p>6.2.1 Complete the investigation within a defined timeframe, considering the urgency and potential impact on product quality. <\/p>\n\n\n\n<p>6.2.2 Provide regular updates to relevant stakeholders during the investigation process.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"87_Corrective_Actions\"><\/span><strong>8<\/strong>.<strong>7. Corrective Actions:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>7.1 Immediate Corrective Actions:<\/strong> <\/p>\n\n\n\n<p>7.1.1 Implement immediate corrective actions to address the deviation and prevent its recurrence. <\/p>\n\n\n\n<p>7.1.2 Document these actions in the deviation report.<\/p>\n\n\n\n<p><strong>7.2 Preventive Actions:<\/strong> <\/p>\n\n\n\n<p>7.2.1 Propose and implement preventive actions to avoid similar deviations in the future. <\/p>\n\n\n\n<p>7.2.2 Communicate preventive measures to relevant personnel through training or procedural updates.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"88_Review_and_Approval\"><\/span>8.<strong>8. Review and Approval:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>8.1 QA will review the completed deviation report, investigation findings, and corrective actions. <\/p>\n\n\n\n<p>8.2 Obtain approval from relevant stakeholders before closing the deviation.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"89_Reporting\"><\/span>8.<strong>9. Reporting:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>9.1 Communicate the resolution and outcomes of the deviation investigation to all concerned parties. <\/p>\n\n\n\n<p>9.2 Include a summary of lessons learned and recommendations for continuous improvement.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"810_Training\"><\/span>8.<strong>10. Training:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>10.1 Provide additional training to personnel involved in the deviation, emphasizing the importance of adherence to procedures. <\/p>\n\n\n\n<p>10.2 Document training sessions and maintain records.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"811_Revision_History\"><\/span>8.<strong>11. Revision History:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>11.1 Document all revisions made to the deviation handling procedures. <\/p>\n\n\n\n<p>11.2 Clearly communicate any changes to relevant personnel.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"812_References\"><\/span>8.<strong>12. References:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>12.1 List any relevant documents, guidelines, or standards referenced in this SOP.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"9_Training\"><\/span><strong>9. Training:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>9.1 Ensure personnel involved in testing are trained on this SOP. <\/p>\n\n\n\n<p>9.2 Periodically review and update training records.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"10_Revision_History\"><\/span><strong>10. Revision History:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>10.1 Maintain a record of all revisions made to this SOP.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"11_References\"><\/span><strong>11. References:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>11.1 List any relevant documents or standards referenced in this SOP.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"12_Approval\"><\/span><strong>12. Approval:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>12.1 This SOP is approved by the Quality Assurance Manager.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"13_Distribution\"><\/span><strong>13. Distribution:<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>13.1 Distribute copies of this SOP to relevant departments.<\/p>\n\n\n\n<p>For more articles,&nbsp;<strong><a href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/ayurveda\/\">Kindly Click<\/a>&nbsp;here<\/strong>.<\/p>\n\n\n\n<p>For pharmaceutical&nbsp;<a href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/jobs\/\">jobs<\/a>, follow us on<strong>&nbsp;<a href=\"https:\/\/www.linkedin.com\/company\/pharmaceuticalcarrier\/?viewAsMember=true\" target=\"_blank\" rel=\"noreferrer noopener\">LinkedIn<\/a><\/strong><\/p>\n\n\n\n<p><strong>For more&nbsp;<a href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/jobs\/\">jobs<\/a>, kindly visit our job section.<\/strong><\/p>\n\n\n\n<p><a href=\"https:\/\/pharmaceuticalcarrier.com\/index.php\/jobs\/\">www.pharmaceuticalcarrier.com\/Jobs<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;Discover the essence of precision and quality with our cutting-edge solutions. Explore a range of innovative products designed to meet your unique needs. Uncover unparalleled performance and reliability as we redefine excellence in [Your Industry]. Elevate your experience with [Your Company], where excellence meets innovation.&#8221;<\/p>\n","protected":false},"author":1,"featured_media":5599,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","footnotes":""},"categories":[165],"tags":[1615,1613,1612,1611,1289,1609,473,1614,308,1610],"class_list":["post-7075","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-standard-operating-procedure","tag-your-company","tag-your-industry","tag-cutting-edge-technology","tag-excellence","tag-explore","tag-innovate","tag-precision","tag-quality-solutions","tag-reliability","tag-unparalleled-performance"],"uagb_featured_image_src":{"full":["https:\/\/pharmaceuticalcarrier.com\/wp-content\/uploads\/2023\/09\/Standard-operating-procedure.jpg",1200,720,false],"thumbnail":["https:\/\/pharmaceuticalcarrier.com\/wp-content\/uploads\/2023\/09\/Standard-operating-procedure-150x150.jpg",150,150,true],"medium":["https:\/\/pharmaceuticalcarrier.com\/wp-content\/uploads\/2023\/09\/Standard-operating-procedure-300x180.jpg",300,180,true],"medium_large":["https:\/\/pharmaceuticalcarrier.com\/wp-content\/uploads\/2023\/09\/Standard-operating-procedure-768x461.jpg",640,384,true],"large":["https:\/\/pharmaceuticalcarrier.com\/wp-content\/uploads\/2023\/09\/Standard-operating-procedure-1024x614.jpg",640,384,true],"1536x1536":["https:\/\/pharmaceuticalcarrier.com\/wp-content\/uploads\/2023\/09\/Standard-operating-procedure.jpg",1200,720,false],"2048x2048":["https:\/\/pharmaceuticalcarrier.com\/wp-content\/uploads\/2023\/09\/Standard-operating-procedure.jpg",1200,720,false],"authorship-box-avatar":["https:\/\/pharmaceuticalcarrier.com\/wp-content\/uploads\/2023\/09\/Standard-operating-procedure-150x150.jpg",150,150,true],"authorship-box-related":["https:\/\/pharmaceuticalcarrier.com\/wp-content\/uploads\/2023\/09\/Standard-operating-procedure-70x70.jpg",70,70,true],"sow-carousel-default":["https:\/\/pharmaceuticalcarrier.com\/wp-content\/uploads\/2023\/09\/Standard-operating-procedure.jpg",272,163,false]},"uagb_author_info":{"display_name":"Pharmacareer","author_link":"https:\/\/pharmaceuticalcarrier.com\/index.php\/author\/grandirpharmagmail-com\/"},"uagb_comment_info":1,"uagb_excerpt":"\"Discover the essence of precision and quality with our cutting-edge solutions. Explore a range of innovative products designed to meet your unique needs. Uncover unparalleled performance and reliability as we redefine excellence in [Your Industry]. Elevate your experience with [Your Company], where excellence meets innovation.\"","amp_enabled":true,"_links":{"self":[{"href":"https:\/\/pharmaceuticalcarrier.com\/index.php\/wp-json\/wp\/v2\/posts\/7075","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharmaceuticalcarrier.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmaceuticalcarrier.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmaceuticalcarrier.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaceuticalcarrier.com\/index.php\/wp-json\/wp\/v2\/comments?post=7075"}],"version-history":[{"count":3,"href":"https:\/\/pharmaceuticalcarrier.com\/index.php\/wp-json\/wp\/v2\/posts\/7075\/revisions"}],"predecessor-version":[{"id":7083,"href":"https:\/\/pharmaceuticalcarrier.com\/index.php\/wp-json\/wp\/v2\/posts\/7075\/revisions\/7083"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaceuticalcarrier.com\/index.php\/wp-json\/wp\/v2\/media\/5599"}],"wp:attachment":[{"href":"https:\/\/pharmaceuticalcarrier.com\/index.php\/wp-json\/wp\/v2\/media?parent=7075"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmaceuticalcarrier.com\/index.php\/wp-json\/wp\/v2\/categories?post=7075"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmaceuticalcarrier.com\/index.php\/wp-json\/wp\/v2\/tags?post=7075"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}